206 related articles for article (PubMed ID: 16828888)
1. Recent development of therapeutics for chronic HCV infection.
Huang Z; Murray MG; Secrist JA
Antiviral Res; 2006 Sep; 71(2-3):351-62. PubMed ID: 16828888
[TBL] [Abstract][Full Text] [Related]
2. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
Chen SH; Tan SL
Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
Koch U; Narjes F
Curr Top Med Chem; 2007; 7(13):1302-29. PubMed ID: 17627559
[TBL] [Abstract][Full Text] [Related]
4. Resistance mutations against HCV protease inhibitors and antiviral drug design.
Shang L; Lin K; Yin Z
Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
6. TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection.
Tsantrizos YS
Curr Opin Investig Drugs; 2009 Aug; 10(8):871-81. PubMed ID: 19649931
[TBL] [Abstract][Full Text] [Related]
7. New targets for antiviral therapy of chronic hepatitis C.
Bühler S; Bartenschlager R
Liver Int; 2012 Feb; 32 Suppl 1():9-16. PubMed ID: 22212566
[TBL] [Abstract][Full Text] [Related]
8. Trial watch: Protease inhibitors show promise against HCV.
Nat Rev Drug Discov; 2009 Jan; 8(1):11. PubMed ID: 19116621
[No Abstract] [Full Text] [Related]
9. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
Naggie S; Patel K; McHutchison J
J Antimicrob Chemother; 2010 Oct; 65(10):2063-9. PubMed ID: 20688770
[TBL] [Abstract][Full Text] [Related]
11. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
Morikawa K; Lange CM; Gouttenoire J; Meylan E; Brass V; Penin F; Moradpour D
J Viral Hepat; 2011 May; 18(5):305-15. PubMed ID: 21470343
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of NS3 protease inhibitors in HCV infection.
Goudreau N; Llinàs-Brunet M
Expert Opin Investig Drugs; 2005 Sep; 14(9):1129-44. PubMed ID: 16144497
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections.
Beaulieu PL; Tsantrizos YS
Curr Opin Investig Drugs; 2004 Aug; 5(8):838-50. PubMed ID: 15600240
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
Lin C; Kwong AD; Perni RB
Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.
Kwong AD; McNair L; Jacobson I; George S
Curr Opin Pharmacol; 2008 Oct; 8(5):522-31. PubMed ID: 18835365
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus.
Kamal S; Shahzad A; Rehman K; Tariq K; Akash MSH; Imran M; Assiri MA
Curr Med Chem; 2024; 31(15):2052-2072. PubMed ID: 37855348
[TBL] [Abstract][Full Text] [Related]
17. Current drug discovery strategies for treatment of hepatitis C virus infection.
Cheng KC; Gupta S; Wang H; Uss AS; Njoroge GF; Hughes E
J Pharm Pharmacol; 2011 Jul; 63(7):883-92. PubMed ID: 21635253
[TBL] [Abstract][Full Text] [Related]
18. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
19. Optimal treatment with telaprevir for chronic HCV infection.
Jesudian AB; Jacobson IM
Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
[TBL] [Abstract][Full Text] [Related]
20. New horizons in hepatitis C antiviral therapy with direct-acting antivirals.
Aghemo A; De Francesco R
Hepatology; 2013 Jul; 58(1):428-38. PubMed ID: 23467911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
